RBL2/DREAM-Mediated Repression of the Aurora Kinase A/B Pathway Determines Therapy Responsiveness and Outcome in p53 WT NSCLC

Researchers found heightened expression of RB-family (RBL) 2 and reduced expression of AURKA/B pathway genes was associated with improved outcomes in p53 wild-type but not p53 mutant NSCLC patients.